Valproate treatment of acute alcohol hallucinosis: A double-blind, placebo-controlled study

Alcohol and Alcoholism

Volumn 43, Issue 4, 2008, Pages 456-459

  Aliyev, Zafar N ^a   Aliyev, Nadir A ^b  

^a Narcological Dispensary of Ministry of Health of Azerbaijan Republic   (Azerbaijan)

^b Dispensary of Mental Hygiene ^*  (Azerbaijan)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DEPAKENE CHRONO; PLACEBO; VALPROIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HALLUCINOSIS; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; PARALLEL DESIGN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRUCTURED INTERVIEW;

ACUTE DISEASE; ADULT; ALCOHOLISM; ANTICONVULSANTS; DOUBLE-BLIND METHOD; FEMALE; HALLUCINATIONS; HUMANS; MALE; VALPROIC ACID;

EID: 47049130162     PISSN: 07350414     EISSN: 14643502     Source Type: Journal    
DOI: 10.1093/alcalc/agn043     Document Type: Article

References (39)

1. Aliyev ZN, Aliyev NA. (2004) The role of amino-acid transmitters in the pathogenesis of acute alcohol hallucinosis and its treatment with new anticonvulsants. Narcology (in Russian) 12:48-53.
2. Aliyev NA, Aliyev ZN. (2008) Valproate (Depakine-Chrono) in the acute treatment of outpatients with goneralized anxiety disorder without psychiatric.comorbidity: Randomized, double-blind placebo-controlled study. Eur Psychiatry 23:109-14.
3. Anonymous. (2008) Available at http://www.rxabbott.com/pdf/depakote.pdf Valproic acid prescribing information (accessed 24 April 2008).
4. Apud JA. Casanueva F, Civan C et al. (1981) Central nervous system derived GABA influences, plasma GABA concentrations and prolactin secretion. Br J Pharmcol 72:150-1.
5. Baetz M, Bowen RC. (1998) Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 4:73-7.
6. Balfour JA, Bryson W (1994) Valproic acid. A review of its pharmacology and therapeutic potential in indication other than epilepsy. CNS Drugs 2:144-73.
7. Barros HM, Tannhauser MA, Tannhauser M. (1992) Effect of sodium valporate on the open-field behavior of rats. Br J Med Biol Res 25:281-7.
8. Becker HC, Anton RF. (1990) Valproate potentiates and picrotoxin antagonizes the anxiolytic action of ethanol in a nonshock conflict task. Neuropharmacology 29:837-43
9. Book SW, Myrick H. (2005) Novel anticonvulsants in the treatment of alcoholism. Expert Opin Invest Drugs 14:371-6.
10. Brady KT, Myrick H, Henderson S et al. (2002) The use of divalproex in alcohol relapse prevention: A pilot study. Drug Alcohol Depend 67:323-30.
11. Bruens, JH. (1971) Psychosis in epilepsy Psychiatr Neurol Neurochir (Amsterdam) 74:175-92.
12. Clark RD, Caive JM, Calais LA et al. (1999) Divalproex in posttraumatic stress disorder: An open-label clinical trial. J Trauma Stress 12:395-401
13. Corbett R, Fielding S, Cornfeldt M et al. (1991) GABA-mimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures. Psychopharmacology (Berl) 104 312-6.
14. Dalvi A, Rodgers RJ. (2001) Anxiolytic effects of valproate and diazepam in mice are differentially sensitive to picrotoxin antagonism. Pharmacol Biochem 68:23-32.
15. Davis LL, Ryan W, Adinoff B et al. (20001 Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 20 (Suppl 1):1S-17S.
16. De Angelis L. (1995) Effects of valproate and lorazepam on experimental anxiety: Tolerance, withdrawal, and role of clonidine. Pharmacol Biochem Behav 52:329-33.
17. Glantz AS. (1999) Primer of Biostatistics, 4th edn (Russian translation from English by J.A. Danilov). Moscow, Russia: Practice, 459 pp.
18. Hertzman M. (2000) Divalproex sodium to treat concomitant substance abuse and mood disorders. J Subst Misuse Treat 18:371-2.
19. Johnson Bankole A, Swift Robert M, Ait-Daoud Nassima et al. (2004) Development of novel pharmacotherapies for the treatment of alcohol dependence: Focus on antiepileptics. Diagnosis and treatment. Alcohol Clin Exp Res. 2:295-301.
20. Kay S, Opler L, Fiszbein A. (1986) Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawada, NY: Multi-Health System, 19 pp.
21. Keck PE Jr, McElroy SL, Friedman LM. (1992) Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 12(Suppl):36S-41S.
22. Keck PE Jr, Me Elroy SL, Tugrul KC et al. (1993) Antiepileptic drugs for treatment of panic disorder. Neuropsychobiology 27 150-3.
23. Lang AP, de Angelis L. (2003) Experimental anxiety and antiepileptics: the effects of valproate and vigabatrin in the mirrored chamber test. Methods Find Exp Clin Pharmacol 25:265-71.
24. Longo LP, Campbell T, Hubatch S. (2002) Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis 21 55-64.
25. Nemeroff CB. (2003) The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 37 133-46.
26. Ontiveros A, Fontaine R. (1992) Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 17 78-80.
27. Raevskii KS, Aleksandrovskii IA, Poirovskii MV et al. (1985) Anxiolytic action of sodium valproate (possible role of gamma-aminobutyric acid in affective disorders (in Russian). J Neuropathol Psychiatry 85:574-9.
28. Reoux JP, Saxon AJ, Malte CA et al. (2001) Divalproex sodium in alcohol withdrawal: A randomized double-blind placebo-controlled clinical trial. Alcohol Clin Expl Res 25:1324-9.
29. Rodina VI, Krupina NA, Kryzhanovslii GN. (1993) A new natural model of elevated anxiety in rats (in Russian). Bull Exp Biol Med 116 127-30.
30. Roy-Byrne PP, Ward NG, Donnely PJ. (1989) Valproate in anxiety and withdrawal syndromes, J. Clin Psychiatry 50:44-8.
31. Shephard RA. (1987) Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action. Life Sci 40:2429-36.
32. Simiand J, Keane PE, Morre M. (1984) The staircase test in mice: A simple and efficient procedure for primary screening agents. Psychopharmacology (Berl) 84:48-53.
33. Soyka M, Voelckler A. (1988) Side effects and efficiency of neuroleptic treatment in alcohol hallucinosis. In: Waahlberg RB (ed). Proceedings of the 35th International Congress on Alcoholism and Drug Dependence, (ISAA+CIAT), Vol. 4. Oslo: International Council on Alcohol and Addictions, 437-445
34. Stein DJ, Simeon D, Frenkel M et al. (1995) An open trial of valproate in borderline personality disorder. J Clin Psychiatry 56:506-10.
35. Suzdak PD, Schawartz RD, Skolnic P et al. (1985) Ethanol stimulates gamma-aminobutyric acid receptor mediated chloride transport in rat brain synaptonerosomes. Proc Natl Acad Sci USA 83 4071-5.
36. WHO. (1994) The ICD-10 Classification of Mental and Behavioral Disorder. Diagnostic criteria for research WHO, Geneva.
37. WHO. (2003) Regional Committee for Europe. Fifty-third Session, 8-11 September, Vienna.
38. Woodman CL, Noyes R Jr. (1994) Panic disorder: Treatment with valproate. J Clin Psychiatry 55:134-6.
39. Zachmann M, Tecei P and Nyhen WZ. (1966) The occurrence of aminobutyric acid in human tissues other than brain. Biol Chem Hoppe Seyler 241:1355-8